Phase 3 Data Release

Clinical Trial Results That Are Changing Weight Loss

Retatrutide represents the next evolution in metabolic science. New data showcases unprecedented efficacy in triple-hormone receptor agonism.

24.2%

Mean Weight Loss

At 48 weeks

6,000+

Trial Participants

Global Phase 3

72 Weeks

Study Duration

Gold Standard Trials

Global

Scope

Multi-center sites

TRIUMPH Clinical Program

A comprehensive series of global Phase 3 trials evaluating the safety and efficacy of retatrutide across diverse populations.

Efficacy Milestone 85% Achievement

100%

Weight Loss Achievement

Every participant on the highest dose achieved at least 5% weight reduction.